Compare · ANIP vs LLY
ANIP vs LLY
Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANIP and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 584.9x ANIP ($1.82B).
- Over the past year, ANIP is up 28.4% and LLY is up 49.9% - LLY leads by 21.4 points.
- LLY has been more active in the news (16 items in the past 4 weeks vs 2 for ANIP).
- LLY has more recent analyst coverage (25 ratings vs 11 for ANIP).
- Company
- ANI Pharmaceuticals Inc.
- Eli Lilly and Company
- Price
- $81.17+0.14%
- $1159.61+2.37%
- Market cap
- $1.82B
- $1.07T
- 1M return
- -3.47%
- +18.85%
- 1Y return
- +28.45%
- +49.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 16
- Recent ratings
- 11
- 25
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ANIP
- ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Walsh Patrick D sold $1,127,120 worth of shares (13,973 units at $80.66), decreasing direct ownership by 27% to 38,432 units (SEC Form 4)
- SVP, HEAD - ESTABLISHED BRANDS Rowland Thomas Andrew sold $36,357 worth of shares (459 units at $79.21), decreasing direct ownership by 1% to 38,271 units (SEC Form 4)
- PRESIDENT & CEO Lalwani Nikhil sold $4,266,350 worth of shares (55,000 units at $77.57), decreasing direct ownership by 14% to 349,889 units (SEC Form 4)
- SVP, GENERICS Gutwerg Ori sold $220,374 worth of shares (2,772 units at $79.50), decreasing direct ownership by 3% to 78,696 units (SEC Form 4)
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $39,080 worth of shares (500 units at $78.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.63% to 78,390 units (SEC Form 4)
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by ANI Pharmaceuticals Inc.
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest LLY
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial